These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 37170778)

  • 41. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial.
    Gnant M; Mlineritsch B; Stoeger H; Luschin-Ebengreuth G; Heck D; Menzel C; Jakesz R; Seifert M; Hubalek M; Pristauz G; Bauernhofer T; Eidtmann H; Eiermann W; Steger G; Kwasny W; Dubsky P; Hochreiner G; Forsthuber EP; Fesl C; Greil R;
    Lancet Oncol; 2011 Jul; 12(7):631-41. PubMed ID: 21641868
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Differences between bisphosphonate-related and denosumab-related osteonecrosis of the jaws: a systematic review.
    Querrer R; Ferrare N; Melo N; Stefani CM; Dos Reis PED; Mesquita CRM; Borges GA; Leite AF; Figueiredo PT
    Support Care Cancer; 2021 Jun; 29(6):2811-2820. PubMed ID: 33140246
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials.
    Händel MN; Cardoso I; von Bülow C; Rohde JF; Ussing A; Nielsen SM; Christensen R; Body JJ; Brandi ML; Diez-Perez A; Hadji P; Javaid MK; Lems WF; Nogues X; Roux C; Minisola S; Kurth A; Thomas T; Prieto-Alhambra D; Ferrari SL; Langdahl B; Abrahamsen B
    BMJ; 2023 May; 381():e068033. PubMed ID: 37130601
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Osteonecrosis of the jaw in patients receiving intravenous or oral bisphosphonates.
    King AE; Umland EM
    Pharmacotherapy; 2008 May; 28(5):667-77. PubMed ID: 18447663
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Osteonecrosis of the jaw and use of bisphosphonates in adjuvant breast cancer treatment: a meta-analysis.
    Mauri D; Valachis A; Polyzos IP; Polyzos NP; Kamposioras K; Pesce LL
    Breast Cancer Res Treat; 2009 Aug; 116(3):433-9. PubMed ID: 19521766
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Current situation and future issues of antiresorptive agent-related osteonecrosis of the jaw].
    Takaoka K; Kishimoto H
    Nihon Yakurigaku Zasshi; 2019; 153(1):22-27. PubMed ID: 30643088
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer.
    Guarneri V; Miles D; Robert N; Diéras V; Glaspy J; Smith I; Thomssen C; Biganzoli L; Taran T; Conte P
    Breast Cancer Res Treat; 2010 Jul; 122(1):181-8. PubMed ID: 20361252
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Distinct immunopathology in the early stages between different antiresorptives-related osteonecrosis of the jaw-like lesions in mice.
    Hayano H; Kuroshima S; Sasaki M; Tamaki S; Inoue M; Ishisaki A; Sawase T
    Bone; 2020 Jun; 135():115308. PubMed ID: 32142911
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pathophysiology of Osteonecrosis of the Jaws.
    Aghaloo T; Hazboun R; Tetradis S
    Oral Maxillofac Surg Clin North Am; 2015 Nov; 27(4):489-96. PubMed ID: 26412796
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Survival in older women with early stage breast cancer receiving low-dose bisphosphonates or denosumab.
    Suarez-Almazor ME; Herrera R; Lei X; Chavez-MacGregor M; Zhao H; Giordano SH
    Cancer; 2020 Sep; 126(17):3929-3938. PubMed ID: 32573777
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Osteonecrosis of the jaw in patients transitioning from bisphosphonates to denosumab treatment for osteoporosis.
    Voss PJ; Steybe D; Poxleitner P; Schmelzeisen R; Munzenmayer C; Fuellgraf H; Stricker A; Semper-Hogg W
    Odontology; 2018 Oct; 106(4):469-480. PubMed ID: 29713913
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Osteonecrosis of the Jaw in Patients Receiving Bone-Targeted Therapies: An Overview--Part I.
    Turner B; Drudge-Coates L; Ali S; Pati J; Nargund V; Ali E; Cheng L; Wells P
    Urol Nurs; 2016; 36(3):111-6, 154. PubMed ID: 27501591
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial.
    Coleman R; Finkelstein DM; Barrios C; Martin M; Iwata H; Hegg R; Glaspy J; Periañez AM; Tonkin K; Deleu I; Sohn J; Crown J; Delaloge S; Dai T; Zhou Y; Jandial D; Chan A
    Lancet Oncol; 2020 Jan; 21(1):60-72. PubMed ID: 31806543
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Bisphosphonates and osteonecrosis of the jaw: a retrospective study.
    Murad OM; Arora S; Farag AF; Guber HA
    Endocr Pract; 2007; 13(3):232-8. PubMed ID: 17599853
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Medication-related osteonecrosis of the jaw: risk factors in patients under biphosphonate versus patients under antiresorptive-antiangiogenic drugs.
    Ghidini G; Manfredi M; Giovannacci I; Mergoni G; Sarraj A; Mureddu M; Giunta G; Bonanini M; Meleti M; Vescovi P
    Minerva Stomatol; 2017 Aug; 66(4):135-140. PubMed ID: 28497661
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel.
    Hadji P; Coleman RE; Wilson C; Powles TJ; Clézardin P; Aapro M; Costa L; Body JJ; Markopoulos C; Santini D; Diel I; Di Leo A; Cameron D; Dodwell D; Smith I; Gnant M; Gray R; Harbeck N; Thurlimann B; Untch M; Cortes J; Martin M; Albert US; Conte PF; Ejlertsen B; Bergh J; Kaufmann M; Holen I
    Ann Oncol; 2016 Mar; 27(3):379-90. PubMed ID: 26681681
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Osteonecrosis of the jaw related to non-antiresorptive medications: a systematic review.
    Nicolatou-Galitis O; Kouri M; Papadopoulou E; Vardas E; Galiti D; Epstein JB; Elad S; Campisi G; Tsoukalas N; Bektas-Kayhan K; Tan W; Body JJ; Migliorati C; Lalla RV;
    Support Care Cancer; 2019 Feb; 27(2):383-394. PubMed ID: 30353228
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Does adjuvant bisphosphonate in early breast cancer modify the natural course of the disease? A meta-analysis of randomized controlled trials.
    Mauri D; Valachis A; Polyzos NP; Tsali L; Mavroudis D; Georgoulias V; Casazza G
    J Natl Compr Canc Netw; 2010 Mar; 8(3):279-86. PubMed ID: 20202461
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Position paper on medication-related osteonecrosis of the jaw (MRONJ)].
    Svejda B; Muschitz Ch; Gruber R; Brandtner Ch; Svejda Ch; Gasser RW; Santler G; Dimai HP
    Wien Med Wochenschr; 2016 Feb; 166(1-2):68-74. PubMed ID: 26847441
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Real-world study of antiresorptive-related osteonecrosis of jaw based on the US food and drug administration adverse event reporting system database.
    Peng J; Wang H; Liu Z; Xu ZL; Wang MX; Chen QM; Wu ML; Ren XL; Liang QH; Liu FP; Ban B
    Front Pharmacol; 2022; 13():1017391. PubMed ID: 36339548
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.